Health Insurance Innovations (Nasdaq:HIIQ), a leading developer and virtual administrator of affordable, cloud-based individual health insurance plans and ancillary products, announced record sales results for the first quarter ended March 31, 2014. Health Insurance Innovations Inc (NASDAQ:HIIQ), shares after opening at $10.00 moved to $12.08 on last trade day and at the end of the day closed at $12.00. Company price to sales ratio in past twelve months was calculated as 2.94 and price to cash ratio as 7.71. Health Insurance Innovations Inc (NASDAQ:HIIQ), showed a positive weekly performance of 18.93%.
On Tuesday, a negative article on Seeking Alpha appeared to make investors decide they didn’t like stock in mining company Uranium Energy Corp. (UEC) anymore to the tune of a 16.26-percent sell-off. Then, on Wednesday, they appeared to come to the conclusion that their initial decision was a bad one to the tune of a 16.50-percent gain. Uranium Energy Corp. (NYSEMKT:UEC), shares advanced 16.50% in last trading session and ended the day on $1.20. Uranium Energy Corp. (NYSEMKT:UEC), return on equity ratio is recorded as -38.90% and its return on assets is -31.20%. Uranium Energy Corp. (NYSEMKT:UEC), yearly performance is -40.59%.
Oppenheimer assumed coverage on shares of Dipexium Pharmaceuticals (NASDAQ:DPRX) in a report released on Monday, TheFlyOnTheWall.com reports. The firm issued an outperform rating and a $27.00 price objective on the stock. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), shares moved up 16.33% in last trading session and was closed at $10.40, while trading in range of $ 8.79 – 10.54. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), year to date (YTD) performance is -25.93%.
On April 8, 2014, Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any. Venaxis Inc (NASDAQ:APPY), weekly performance is 9.27%. On last trading day company shares ended up $6.01. Venaxis Inc (NASDAQ:APPY), distance from 50-day simple moving average (SMA50) is 8.64%. Analysts mean target Price for the company is $10.00.